Substance / Medication

Daunorubicin liposome

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
The Clinical Safety and Efficacy of Cytarabine and Daunorubicin Liposome (CPX-351) in Acute Myeloid Leukemia Patients: A Systematic Review.
Alzahrani Abdulwahab M, Alnuhait Mohammed A, Alqahtani Tariq · Cancer Rep (Hoboken) · 2025
PMID: 40348597ObservationalFull text (PMC)
Combination of targeted daunorubicin liposomes and targeted emodin liposomes for treatment of invasive breast cancer.
Fu Min, Tang Wei, Liu Jing-Jing et al. · J Drug Target · 2020
PMID: 31462111Review
A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia.
Usuki Kensuke, Miyamoto Toshihiro, Yamauchi Takuji et al. · Int J Hematol · 2024
PMID: 38532078TrialFull text (PMC)
Construction of Functional Targeting Daunorubicin Liposomes Used for Eliminating Brain Glioma and Glioma Stem Cells.
Zhao Wei-Yu, Zhang Cheng-Xiang, Liu Lei et al. · J Biomed Nanotechnol · 2016
PMID: 29336535Preclinical
Preparation, therapeutic efficacy and intratumoral localization of targeted daunorubicin liposomes conjugating folate-PEG-CHEMS.
Xiong Subin, Yu Bo, Wu Jun et al. · Biomed Pharmacother · 2011
PMID: 21177069Preclinical
Pharmacokinetics and tissue distribution of dual-targeting daunorubicin liposomes in mice.
Ying Xue, Wen He, Yao Hong-Juan et al. · Pharmacology · 2011
PMID: 21282968Preclinical
Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals.
Ying Xue, Wen He, Lu Wan-Liang et al. · J Control Release · 2010
PMID: 19799948Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Daunorubicin liposome (substance)
SNOMED CT
413948005
UMLS CUI
C0717668

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.